A carregar...
FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma
On August 16, 2018, the U.S. Food and Drug Administration approved lenvatinib (Lenvima, Eisai Inc.) for first‐line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on an international, multicenter, randomized, open‐label, noninferiority trial (REFLECT; NCT01...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7930400/ https://ncbi.nlm.nih.gov/pubmed/33044793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13566 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|